CSS
ALLO icon

Cubist Systematic Strategies’s Allogene Therapeutics ALLO Stock Holding History

Cubist Systematic Strategies’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$127K Buy
+102,771
New +$123K ﹤0.01% 2743
2024
Q1 		– Sell
-82,544
Closed -$265K – 3665
2023
Q4 		$265K Sell
82,544
-131,600
-61% -$373K ﹤0.01% 2844
2023
Q3 		$679K Buy
214,144
+194,241
+976% +$851K 0.01% 2136
2023
Q2 		$98.9K Sell
19,903
-452,739
-96% -$2.45M ﹤0.01% 2996
2023
Q1 		$2.33M Buy
472,642
+183,643
+64% +$1.18M 0.01% 1554
2022
Q4 		$1.82M Sell
288,999
-290,246
-50% -$2.69M 0.01% 1933
2022
Q3 		$6.26M Buy
579,245
+304,445
+111% +$4.14M 0.04% 852
2022
Q2 		$3.13M Buy
274,800
+68,767
+33% +$610K 0.02% 1417
2022
Q1 		$1.88M Buy
206,033
+65,243
+46% +$680K 0.02% 1530
2021
Q4 		$2.1M Buy
+140,790
New +$2.48M 0.02% 1321
2021
Q3 		– Sell
-124,598
Closed -$3.25M – 2939
2021
Q2 		$3.25M Buy
124,598
+96,497
+343% +$2.75M 0.04% 787
2021
Q1 		$992K Sell
28,101
-84,220
-75% -$2.84M 0.01% 1542
2020
Q4 		$2.83M Buy
+112,321
New +$3.66M 0.04% 748
2020
Q3 		– Sell
-11,943
Closed -$511K – 2473
2020
Q2 		$511K Sell
11,943
-2,069
-15% -$74.8K 0.01% 1577
2020
Q1 		$272K Sell
14,012
-24,821
-64% -$591K 0.01% 1571
2019
Q4 		$1.01M Buy
+38,833
New +$1.07M 0.02% 1153

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Cubist Systematic Strategies's ALLO Position: Q3 2025 in Review

Cubist Systematic Strategies opened a new position in Allogene Therapeutics (ALLO) in Q3 2025: 102,771 shares worth $127K. The stake represents ﹤0.01% of the portfolio and ranks #2743 among its holdings. This is a return to the name: Cubist Systematic Strategies previously reported a position in ALLO as recently as Q4 2023.

Cubist Systematic Strategies first reported a position in ALLO in Q4 2019 and has held it in 16 quarters since. The position peaked at $6.26M in Q3 2022. 170 funds tracked by Wall St. Rank hold ALLO as of Q3 2025.

  • Cubist Systematic Strategies held 102,771 shares of Allogene Therapeutics worth $127K as of Q3 2025.
  • Allogene Therapeutics was a new Cubist Systematic Strategies position in Q3 2025.
  • Allogene Therapeutics made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2743 holding.
  • Cubist Systematic Strategies first reported a position in Allogene Therapeutics in Q4 2019 and has held it in 16 quarters since.
  • Cubist Systematic Strategies's Allogene Therapeutics position peaked at $6.26M in Q3 2022.
  • 170 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.